Foundayo (Orforglipron): Results, Dose & Cost

Every few months a new "GLP-1 pill" headline circulates, and most of them are describing Rybelsus, the existing FDA-approved oral form of semaglutide. Orforglipron, approved by the FDA as Foundayo on April 1, 2026³, is a genuinely different kind of drug, and the distinction matters for anyone trying to plan around it.

How is Foundayo different from Rybelsus?

Rybelsus is oral semaglutide — a peptide, the same class of molecule as the injectable GLP-1s, formulated with an absorption enhancer to survive the gut and make it into the bloodstream. That formulation trick is also why Rybelsus has to be taken on a fasted stomach with a small sip of water and a 30-minute wait before eating. Foundayo's label, by contrast, says to take it once daily with or without food⁴. Orforglipron is structurally different: a small-molecule, non-peptide GLP-1 receptor agonist, which is a much easier class of drug to manufacture at scale and doesn't carry the same absorption-fragility problem¹. That manufacturing difference is a large part of why it's being watched as closely as it is — a small-molecule GLP-1 is cheaper and simpler to produce than a peptide, which has direct implications for future supply and price once it reaches market.

How much weight do people lose on Foundayo?

The FDA label reports two 72-week, placebo-controlled trials, one in adults without diabetes and one in adults with type 2 diabetes, run with an investigational orforglipron formulation and expressed as the equivalent Foundayo doses. Everyone also got diet and activity counseling. Average weight change from baseline at week 72⁴:

Those are averages across everyone randomized, including people who stopped the drug, so some individuals lost far more and some far less. Weight loss was smaller in the diabetes trial, the same pattern seen with the injectable GLP-1s.

In the pivotal Phase 2 obesity trial, daily oral orforglipron produced clinically meaningful weight loss over 36 weeks compared with placebo, with a safety and tolerability profile broadly consistent with the injectable GLP-1 class — chiefly gastrointestinal side effects during dose escalation¹. The Phase 2 results were strong enough to move the drug into a full Phase 3 program, and a randomized, double-blind Phase 3b maintenance trial has since specifically evaluated orforglipron's ability to sustain weight reduction over the longer term, rather than just produce it² — a meaningfully different clinical question, since a drug that works for a few months and one that keeps working for years are not automatically the same drug in practice. Orforglipron is now approved: FDA cleared it as Foundayo under application NDA 220934 on April 1, 2026, with a further supplement approved on August 4, 2026³. Trial figures are still trial figures, though — they describe what happened in a controlled study population, not what an approved label promises any individual.

What dose is Foundayo, and how much does it cost?

Per the label, Foundayo starts at 0.8 mg once daily. After at least 30 days you move to 2.5 mg, then after at least 30 more days to 5.5 mg. From there your prescriber can step up to 9 mg, 14.5 mg and 17.2 mg, each after at least 30 days on the dose before, based on how well it works and how well you tolerate it. The maximum is 17.2 mg a day, and you never take more than one tablet a day⁴.

Eli Lilly prices Foundayo by dose. The regular self-pay figures below are from Lilly's Foundayo coverage and savings page, read in October 2026, where a month means a 30-day supply⁵:

The same page lists two other routes: as little as $25 a month with a Foundayo savings card if your commercial insurance covers the drug, and a $50 monthly copay through Medicare's GLP-1 Bridge program for people who qualify⁵. Offers carry eligibility rules and expiration dates, so check the current terms before your first fill.

What are Foundayo's side effects?

Stomach and gut effects lead the list, and they rise with the dose. In the label's pooled data from the two weight trials, these were the most common reactions⁴:

About 8% of people on Foundayo stopped because of side effects, compared with 3% on placebo, and most of those stops were for gut symptoms⁴. The slow 30-day steps exist to soften exactly this. Like the injectable GLP-1s, Foundayo carries a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2⁴.

Where does Foundayo fit next to Rybelsus and the injectables?

Now that it is approved, orforglipron competes directly with Rybelsus as an oral option, and indirectly with every injectable on the market, on a single axis: convenience without a needle. On price it launched inside the same self-pay band as the brand injectables, at $149 to $349 a month by dose, rather than at the premium list prices Wegovy and Zepbound carried at launch⁵. Compounded alternatives can still undercut it, with the trade-offs that come with compounding. Anyone weighing oral options should price all of them side by side — see oral semaglutide (Rybelsus) vs Wegovy for that comparison, including why Rybelsus's own absorption limits cap how much weight loss it typically delivers relative to the injectable form.

What does approval not settle?

An approval is not coverage. Foundayo is sold through Eli Lilly's own direct channel — see our LillyDirect Foundayo entry — and a brand-name launch price is set by the manufacturer, not by the competition it will eventually face. Medicare's GLP-1 Bridge demonstration includes Foundayo at a $50 monthly copay for eligible beneficiaries, which is covered in does insurance cover Zepbound and Wegovy, but that is a narrow, time-limited program rather than a general answer. For how Foundayo compares with the Wegovy pill and the weekly shot, see Wegovy pill vs injection. The amylin drugs coming up behind it are in CagriSema and the amylin pipeline. If you are deciding what to do about your weight this year, price every route side by side — see the full cost-per-month comparison across brand and compounded providers — rather than assuming a new approval is automatically the cheapest one. We track drugs like this specifically because a data-forward site should tell you what's real evidence versus what's still projection; the primary sources behind this piece, along with every FDA-approved comparison on the site, are indexed in our research library. Not medical advice — see our medical disclaimer.